SION Sionna Therapeutics, Inc.
Company Analysis
Latest News
🔴 Sionna Therapeutics is trading 6.2% down today as biotech sector reverses Wednesday’s rally
Sionna Therapeutics is trading 6.2% down now at $5.86 after the broader biotech sector reversed Wednesday’s rally. - Biotech ETF XBI is down 2.47% during the...
🟢 Sionna Therapeutics rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Sionna Therapeutics investigated, following 91% stock plunge on failed drug trial
The Law Offices of Howard G. Smith launched an investigation into Sionna Therapeutics on August 18, 2026. The firm is investigating potential violations of...
🔴 Sionna Therapeutics is trading 5.6% down today after Phase 2a failure of SION-719
Sionna Therapeutics is trading 5.6% down now at $6.10, following the August 10 Phase 2a failure of SION-719. - Sionna stopped advancing SION-719 as an add-on...
🟢 Sionna Therapeutics is trading 5% up today after August 10 Phase 2a failure
Sionna Therapeutics is trading 5.20% higher at $6.58 after a volatile rebound following the August 10 Phase 2a failure. - SION-719 produced a -1.0 mmol/L...
🟢 Sionna Therapeutics is trading 10.98% up today after its August 10 Phase 2a failure
Sionna Therapeutics is trading 10.98% up now at $5.66 amid a volatile rebound after its August 10 Phase 2a failure. - SION-719 produced a -1.0 mmol/L...
🟢 Sionna Therapeutics is trading 8.24% up today after volatile rebound from trial failure
Sionna Therapeutics is trading 8.24% up at $5.46, following a highly volatile rebound after the August 10 Phase 2a trial failure. - The company discontinued...
Sionna Discontinues SION-719 Cystic Fibrosis Program After Negative Phase 2a Data
Sionna Therapeutics announced that its Phase 2a trial for SION-719 in cystic fibrosis (CF) did not meet its key endpoint, leading the company to discontinue...
Sionna's $2 Billion Wipeout: Can a Cash Pile Save a Company Whose Science Just Failed?
Shares cratered as Sionna Therapeutics lost 92% of its market value in a single session after its lead cystic fibrosis drug produced results statistically...
Sionna Therapeutics shares crater 92%, following failed cystic fibrosis drug trial
Sionna Therapeutics (SION) shares plummeted approximately 92%. The company's experimental cystic fibrosis drug, SION-719, failed a Phase 2a clinical trial. The...